Stock Commentary - Europe - week to Dec 1, 2008

8 December 2008

EUROPEAN: bourses, with the exception of Switzerland, were down to some degree, in what was another volatile week for markets in the reporting period to December 1. The last day was particularly poor, as Wall Street plunged and European investors took stock of the fact that a deeper and longer recession was anticipated. Pharmaceutical issues had several good sessions, outperforming domestic markets, but others when they moved into negative territory. The sector was not helped by the European Commission's raids on drugmakers aimed at revealing market distortion and then its report finding that some had blocked generics (see pages 11-12). In ZURICH, where the SMI notched up 1.1% on the week, defensive issues were in favor on November 28, Roche moved up 4.5% with Novartis rising 4.4%, but they ended 1.0% higher and unchanged, respectively. FRANKFURT saw the Xetra Dax fall 3.5%, but Merck KGaA advanced 2.7%, helped by news of European Union approval of extended use for its cancer drug Erbitux (cetuximab; see page 23).

LONDON: saw a mixed performance in the drug sector, with this seeing defensive buying on November 28, when AstraZeneca, GlaxoSmithKline and Shire advanced 5.3%, 5.1% and 6.2%, respectively, but they failed to hold on to these gains, ending the week -2.1%, -4.1% and +0.3%, respectively. Little Antisoma was the star of the week, with a rise of 15.9%. The view among some observers was that there would be further consolidation in the biotechnology sector and Antisoma may be a target, as could Ark Therapeutics and York Pharma (both not tracked). Protherics still traded 9.3% higher, despite having been taken over by BTG (see page 28).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight